U.S. FDA Approval for Expanded Labels
In March 2024, Esperion Therapeutics received U.S. FDA approval for the expanded labels of NEXLETOL and NEXLIZET, making them the only FDA-approved nonstatins to lower LDL-cholesterol and reduce the risk of myocardial infarction and coronary revascularization in both primary and secondary prevention patients.
Significant Revenue Growth
Fourth quarter 2024 total revenue was $69.1 million, an increase of 114% compared to $32.3 million in the fourth quarter of 2023. U.S. net product revenue increased by approximately 52%.
Global Expansion and Partnerships
Esperion entered into partnerships with CSL Seqirus and Neopharm Israel to commercialize NEXLETOL and NEXLIZET in Australia, New Zealand, and Israel. A new drug application was also submitted in Japan by partner Otsuka.
Strong International Performance
Royalty revenue from DSE increased 9% sequentially to $9.7 million in the fourth quarter of 2024, with full-year royalty revenue increasing 116% year-over-year to $32.6 million.
Robust Financial Strategy
Esperion executed financial transactions, including a $304.7 million royalty purchase agreement and a $150 million secured term loan facility, reshaping their capital structure and providing financial flexibility.